Cargando…

Risk Factors for Immune Checkpoint Inhibitor–Mediated Cardiovascular Toxicities

PURPOSE OF REVIEW: Immune checkpoint inhibitors (ICIs) have improved the field of cancer, especially in patients with advanced malignancies. Nevertheless, cardiovascular immune-related adverse events (irAEs) with high mortality and morbidity have been observed, including myocarditis, pericarditis, a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yousif, Laura I., Screever, Elles M., Versluis, Daniëlle, Aboumsallem, Joseph Pierre, Nierkens, Stefan, Manintveld, Olivier C., de Boer, Rudolf A., Meijers, Wouter C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10256640/ https://www.ncbi.nlm.nih.gov/pubmed/37079251 http://dx.doi.org/10.1007/s11912-023-01414-4

Ejemplares similares

Multifactorial Diseases of the Heart, Kidneys, Lungs, and Liver and Incident Cancer: Epidemiology and Shared Mechanisms
por: Shi, Canxia, et al.
Publicado: (2023)

Circulating immune checkpoints predict heart failure outcomes
por: Screever, Elles M., et al.
Publicado: (2023)

Diffuse Myocardial Fibrosis on Cardiac Magnetic Resonance Imaging Is Related to Galectin-3 and Predicts Outcome in Heart Failure
por: Screever, Elles M., et al.
Publicado: (2023)

The role of immune checkpoints in cardiovascular disease
por: Yousif, Laura I., et al.
Publicado: (2022)

Established Tumour Biomarkers Predict Cardiovascular Events and Mortality in the General Population
por: Bracun, Valentina, et al.
Publicado: (2021)

Reverse Cardio‐Oncology: Cancer Development in Patients With Cardiovascular Disease
por: Aboumsallem, Joseph Pierre, et al.
Publicado: (2020)

Fibrotic Marker Galectin-3 Identifies Males at Risk of Developing Cancer and Heart Failure
por: van den Berg, Pieter F., et al.
Publicado: (2023)

Kidney Function in Patients With Neuromuscular Disease: Creatinine Versus Cystatin C
por: Screever, Elles M., et al.
Publicado: (2021)

Left atrial volume and left ventricular mass indices in heart failure with preserved and reduced ejection fraction
por: Gehlken, Carolin, et al.
Publicado: (2021)

Evaluation of renal cancer progression in a mouse model of heart failure
por: Shi, Canxia, et al.
Publicado: (2021)

Clonal haematopoiesis of indeterminate potential: associations with heart failure incidence, clinical parameters and biomarkers
por: Shi, Canxia, et al.
Publicado: (2022)

Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors
por: Pirozzi, Flora, et al.
Publicado: (2021)

Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians
por: Raschi, Emanuel, et al.
Publicado: (2023)

The Diagnosis and Management of Immune Checkpoint Inhibitor Cardiovascular Toxicity: Myocarditis and Beyond
por: Gilon, Dan, et al.
Publicado: (2022)

Cardiac Biomarkers in Patients with Cancer: Considerations, Clinical Implications, and Future Avenues
por: Bracun, Valentina, et al.
Publicado: (2020)

Management of Immune Checkpoint Inhibitor Toxicities
por: Durrechou, Quentin, et al.
Publicado: (2020)

Toxicities associated with checkpoint inhibitors—an overview
por: Spiers, Laura, et al.
Publicado: (2019)

Immune Checkpoint Inhibitor–Related Cardiovascular Toxicity in Lung Cancer: Is Routine Screening Indicated?
por: Sun, Lova, et al.
Publicado: (2019)

Cardiovascular toxicity following immune checkpoint inhibitors: A systematic review and meta-analysis
por: Xavier, Camila Bragança, et al.
Publicado: (2022)

Galectin-3 and Blood Group: Binding Properties, Effects on Plasma Levels, and Consequences for Prognostic Performance
por: Pozder, Carolin, et al.
Publicado: (2023)

Anti–Interleukin-6 and Janus Kinase Inhibitors for Severe Neurologic Toxicity of Checkpoint Inhibitors
por: Picca, Alberto, et al.
Publicado: (2021)

Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies
por: Hradska, Katarina, et al.
Publicado: (2021)

Comorbidities complicating heart failure: changes over the last 15 years
por: Screever, Elles M., et al.
Publicado: (2022)

Impact of the gut microbiota on immune checkpoint inhibitor-associated toxicities
por: Pezo, Rossanna C., et al.
Publicado: (2019)

Infections Simulating Immune Checkpoint Inhibitor Toxicities: Uncommon and Deceptive
por: Gudiol, Carlota, et al.
Publicado: (2022)

Immune checkpoint inhibitors in bone metastasis: Clinical challenges, toxicities, and mechanisms
por: Joseph, Gwenyth J., et al.
Publicado: (2023)

Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors
por: De Martin, Eleonora, et al.
Publicado: (2020)

Common risk factors for heart failure and cancer
por: Meijers, Wouter C, et al.
Publicado: (2019)

Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities
por: Xu, Ya, et al.
Publicado: (2020)

Cutaneous Toxicities of Immune Checkpoint Inhibitors: The Role of the Dermatologist
por: Tattersall, Ian William, et al.
Publicado: (2020)

Immune-checkpoint inhibitors: long-term implications of toxicity
por: Johnson, Douglas B., et al.
Publicado: (2022)

Frailty and checkpoint inhibitor toxicity in older patients with melanoma
por: Bruijnen, Cheryl P., et al.
Publicado: (2022)

Imaging features of toxicities associated with immune checkpoint inhibitors
por: Gosangi, Babina, et al.
Publicado: (2022)

Management of pulmonary toxicity associated with immune checkpoint inhibitors
por: Delaunay, Myriam, et al.
Publicado: (2019)

Imaging assessment of toxicity related to immune checkpoint inhibitors
por: Berz, Antonia M., et al.
Publicado: (2023)

Galectin-3 Activation and Inhibition in Heart Failure and Cardiovascular Disease: An Update
por: Suthahar, Navin, et al.
Publicado: (2018)

Immune Checkpoint Inhibitors and Their Cardiovascular Adverse Effects
por: Paluri, Ravi Kumar, et al.
Publicado: (2023)

Gastrointestinal toxicities of immune checkpoint inhibitors: a multicenter retrospective analysis
por: Shieh, Christine, et al.
Publicado: (2021)

Imaging Features of Toxicities by Immune Checkpoint Inhibitors in Cancer Therapy
por: Widmann, Gerlig, et al.
Publicado: (2017)

Campylobacteriosis following immunosuppression for immune checkpoint inhibitor-related toxicity
por: Lee, Karla A, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_c9l5qhmqf48ag4i5b0n2jn6uq4